<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47120">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492802</url>
  </required_header>
  <id_info>
    <org_study_id>POSA-CRP</org_study_id>
    <nct_id>NCT02492802</nct_id>
  </id_info>
  <brief_title>Effect of Inflammation on Pharmacokinetics of Posaconazole</brief_title>
  <official_title>Effect of Inflammation on Pharmacokinetics of Posaconazole</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Posaconazole plasma concentration and inflammatory markers will be determined in all samples
      available from routine analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective observational study will be performed at the University Medical Center
      Groningen, the Netherlands using longitudinal data collection. The design of the study will
      be that patients starting on posaconazole treatment will be evaluated. After informed
      consent is obtained medical data will be collected from the medical chart. Posaconazole
      plasma concentration (trough levels) and inflammatory markers (e.g. C-reactive protein) will
      be determined in all samples available from routine analysis (often daily). This will result
      in a detailed data set capturing day to day variations in inflammation and drug
      concentrations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>posaconazole plasma concentration (mg/L)</measure>
    <time_frame>6 months after start of treatment</time_frame>
    <description>posaconazole drug exposure during treatment in different stages of inflammation</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mycoses</condition>
  <arm_group>
    <arm_group_label>posaconazole-group</arm_group_label>
    <description>patients receiving posaconazole for prophylaxis or treatment of invasive fungal infection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>posaconazole</intervention_name>
    <description>collection plasma samples for measuring posaconazole drug concentration</description>
    <arm_group_label>posaconazole-group</arm_group_label>
    <other_name>noxafil</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  patients with hematological malignancies

          -  immunocompromised patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 yrs

          -  receiving posaconazole

          -  Written informed consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Willem Alffenaar, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMCG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JWC Alffenaar, PharmD, PhD</last_name>
      <phone>050-3614035</phone>
      <email>j.w.c.alffenaar@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Jan-Willem C Alffenaar, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 17, 2016</lastchanged_date>
  <firstreceived_date>July 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>JWC Alffenaar</investigator_full_name>
    <investigator_title>PharmD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
